VBI Vaccines to present at Modern Vaccines Adjuvants & Delivery Systems Conference
The new VBI platform allows researchers to created developed virus-like particle (eVLP) vaccines. These eVLPs are a novel class of synthetic vaccines that are so similar to the structure of a virus that the immune system recognizes them and builds greater immunity.
The event, which is hosted in the Netherlands at the Leiden University Medical Center, offers industrial, academic, regulatory and government groups the opportunity to exchange information about the latest research and strategies for vaccine development. Marc Kirchmeier, vice president of formulation development at VBI Vaccines, will give the presentation. A synopsis will be made available to the public after the presentation has been given.
"Following process improvements and innovations, VBI, with its third-party manufacturers, has demonstrated the ability to manufacture eVLPs at a 50L scale, which in terms of both yield and purity we expect to be suitable for manufacture at a commercial scale," Kirchmeier said. "This is a great stride forward in both our CMV program, and also in demonstrating the potential utility of our eVLP technology in manufacturing other highly potent vaccine and therapeutic candidates."